How compounded GLP-1 medications are made — and how that differs from the branded pens — glp1.how · GLP-1 Guides
How compounded GLP-1 medications are made — and how that differs from the branded pens
A compounded GLP-1 isn't a knockoff pen off a production line — it's mixed from raw active ingredient at a pharmacy. Here's how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy actually makes the vial, and how all of that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.
Updated Sep 2, 2026Evidence-backed
If you've used a compounded GLP-1, you've injected a medication that was mixed from raw ingredients at a pharmacy — not stamped out on the same production line as a branded pen. That distinction shapes everything about how the two are made, tested, and regulated. Here's what actually happens between a barrel of drug powder and the vial in your hand, and how the compounded route compares with the branded one at each step.
What "compounding" actually means
Compounding is the practice of a licensed pharmacy combining or altering ingredients to make a medication for a patient. For GLP-1s, that means starting with the active pharmaceutical ingredient (API) — the drug substance itself, as a powder — and turning it into an injectable solution. This is a fundamentally different activity from manufacturing an FDA-approved drug: a manufacturer makes millions of identical, pre-tested units under federal approval, while a compounder prepares a product that has never been reviewed by the FDA for safety, effectiveness, or quality before it reaches you.
There are two kinds of facility allowed to do this, and the difference matters:
503A pharmacies are state-licensed, compound against an individual prescription for a named patient, are inspected mainly by the state board of pharmacy, and follow the U.S. Pharmacopeia (USP) standards for compounding — including USP <797> for sterile products. They are not required to follow the federal "current good manufacturing practice" (CGMP) rules that manufacturers must.
503B outsourcing facilities register directly with the FDA, can compound larger batches without a patient-specific prescription, and must meet full CGMP and risk-based FDA inspection — a step closer to a manufacturer, but still not making an FDA-approved drug.
Step 1: Sourcing the active ingredient
A legitimate compounder can't just buy GLP-1 powder from anywhere. The API is supposed to be pharmaceutical-grade, come with a valid certificate of analysis documenting its identity and purity, and be made by an establishment registered with the FDA (under section 510 of the federal drug law). Reputable pharmacies send finished product to third-party labs and source raw material from FDA-registered suppliers to try to hold that line.
This is also where one of the biggest safety problems lives — the salt-form issue. The FDA has warned that "salt" versions of the drug substance, such as and , are than what's in the approved medications. The agency says it has no information showing these salts behave the same way in the body, and is not aware of a lawful basis for using them in compounding. Several state pharmacy boards have gone further and prohibited compounding with semaglutide salts or with any API that isn't pharmaceutical-grade and FDA-registered. When you hear cautions about "research peptides" and grey-market powder, this is the core of it: the label on the drum, and where it really came from, is the whole ballgame. (Our guide on covers the grey-market end of this in detail.)
Is compounded semaglutide the same drug as Ozempic or Wegovy?
It's meant to contain the same active ingredient, but it is not the same product. A branded pen is an FDA-approved, factory-made unit reviewed for safety, effectiveness, and quality before it ships. A compounded version is mixed from raw active ingredient at a pharmacy and has not been reviewed by the FDA before it reaches you. The molecule may be the same, but the sourcing, dose-setting, testing, and oversight around it are not.
Where do compounding pharmacies get the semaglutide or tirzepatide?
From the active pharmaceutical ingredient (API) as a raw powder. A legitimate compounder is expected to use pharmaceutical-grade API that comes with a certificate of analysis and is made by an FDA-registered establishment. Where the powder actually comes from is the single biggest quality variable, which is why sourcing and third-party testing matter more than what the finished vial looks like.
What's the problem with semaglutide "salts"?
The FDA has warned that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than what's in the approved medications. The agency says it doesn't have information showing these salts behave the same way in the body, and several state pharmacy boards have prohibited compounding with them. If a pharmacy can't confirm it uses the base drug rather than a salt, that's a meaningful red flag.
Why is a compounded vial more prone to dosing errors than a branded pen?
A branded pen delivers a fixed, metered dose, so there's no measuring to do. A compounded product is often a vial you draw a dose from with a syringe, sometimes at a concentration you're not used to. The FDA has received reports of dosing errors with compounded injectable semaglutide, some serious enough to require hospitalization, several traced to patients drawing up the wrong amount.
Evidence: For & Against
Both sides of the topic, so you can weigh the evidence yourself.
In a 503A setting, the formula starts with a prescription for a specific patient. The prescriber sets the drug, the concentration, and the dose; the pharmacy works out how to dissolve the API to that concentration in a sterile carrier — typically sterile water or a buffered saline solution — sometimes with other excipients to keep the peptide stable. Some compounded products are formulated at concentrations or in drug combinations (for example, paired with vitamin B12) that don't exist in any branded pen.
That flexibility is exactly why compounding exists — and also where risk creeps in. Because a compounded vial isn't a fixed-dose pen, the patient often has to draw up a dose with a syringe, and the concentration may differ from what they're used to. The FDA has received reports of dosing errors — some serious enough to require hospitalization — tied to compounded injectable semaglutide, several traced to patients measuring the wrong amount. A branded pen removes that math; a compounded vial reintroduces it.
Step 3: How the pharmacy actually makes it
The physical process, in a sterile 503A or 503B cleanroom operating under USP <797>, looks roughly like this:
Dissolve the API powder into the sterile carrier at the target concentration.
Sterile-filter the solution, usually through a 0.22-micron filter that removes bacteria.
Aseptically fill the solution into sterile vials in a controlled, clean environment.
Test representative units — reputable operations send samples to third-party labs for potency (is the dose accurate?), sterility (is it free of microbes?), and endotoxin (is it free of the bacterial wall fragments that can cause fever and serious reactions?).
The gap between best practice and worst practice here is enormous, and it's invisible to the patient holding the vial. A careful 503B facility under CGMP tests every batch; a cut-corner operation may test little and document less. Nothing about the finished vial's appearance tells you which one you got — which is why the source matters more than the product looks like it should.
How the branded pens are made
The branded medications — Ozempic and Wegovy (semaglutide, Novo Nordisk), Zepbound and Mounjaro (tirzepatide, Eli Lilly) — are made on an entirely different scale and under an entirely different rulebook.
The drug substance is produced under tight control. Semaglutide is a peptide assembled through large-scale, controlled processes — its peptide backbone is produced by yeast fermentation (recombinant biotechnology) and then chemically modified, at Novo Nordisk's own facilities in Denmark; tirzepatide is likewise made through controlled peptide synthesis. This isn't powder ordered from a supplier; it's produced in-house to a fixed specification.
Every step meets CGMP and FDA approval. The formula and dose aren't set per patient — they're fixed, studied in clinical trials, and approved by the FDA before a single pen is sold. Every batch is made and tested under federal good-manufacturing rules.
Fill-finish is industrial and standardized. The drug is filled into prefilled pens (or vials) at large plants in Denmark, Europe, and the United States, and each unit delivers the same metered dose.
It's slow by design. The full process, from producing the drug substance to a finished, released pen, takes months — one reason branded shortages take months, not days, to resolve.
The through-line: a branded pen is one of millions of identical units, each vetted before it ships. A compounded vial is a small batch prepared after the prescription is written, vetted (if at all) by the pharmacy and its labs rather than by the FDA.
Where compounded GLP-1s stand now
Compounding of these drugs surged because the branded products were in official shortage — a status that, under federal law, opens a window for compounders. As the shortages resolved in 2025, that window narrowed sharply. The FDA ended enforcement discretion for compounded tirzepatide in 2025 (503A pharmacies on February 18, 503B facilities on March 19), and after declaring the semaglutide shortage resolved in February 2025 it ended enforcement discretion for compounded semaglutide on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. Since then, mass-produced "copies" of either drug are no longer permitted; what remains is patient-specific 503A compounding for a documented clinical need. Because this legal status has already shifted more than once and continues to move, treat it as something to re-check against current, dated FDA guidance rather than a settled fact.
If you are using or considering a compounded GLP-1, the practical safeguard is to vet the pharmacy: confirm it's a licensed 503A pharmacy or FDA-registered 503B facility, ask what API it uses and whether it's the base drug (not a salt), and ask for third-party testing. Our guides on pharmacy sources for GLP-1 medications and how to verify a pharmacy is legitimate walk through exactly how.
The bottom line
The difference between a compounded GLP-1 and a branded pen isn't the molecule on the label — it's everything around it: who made the raw ingredient and whether it's the real active drug, whether the dose was set for you or fixed by a manufacturer, whether the sterile process was verified batch-by-batch, and whether any federal body reviewed the finished product before you injected it. Legitimate compounding is a real, regulated pharmacy activity with a genuine role. But the safeguards that come standard with a branded pen are, in the compounded world, only as good as the specific pharmacy behind the vial — which is why sourcing is the part worth your attention.
This article is general education, not medical advice. Regulations governing compounded GLP-1 medications are changing; confirm current status and any specific product with the FDA, your prescriber, or your pharmacist before acting.
Can I still get a compounded GLP-1 now that the branded shortage is over?
The legal window for compounding these drugs narrowed sharply as the branded shortages resolved. The FDA ended enforcement discretion for compounded tirzepatide in early 2025 and for compounded semaglutide on April 22, 2025 (503A pharmacies) and May 22, 2025 (503B facilities), so mass-produced copies are no longer permitted; patient-specific 503A compounding for a documented clinical need remains. This status keeps changing, so check current, dated FDA guidance and confirm with your pharmacist rather than assuming it's settled.
↗
(external link)
Novo Nordisk · Reporting · Moderate evidence
(2026)
Novo Nordisk primary source: polypeptide (insulin and GLP-1) production is based on genetically modified organisms in a contained environment, followed by a multi-step downstream purification that removes the production organism. Replaces an earlier reseller-blog citation; the '250-280 day' production-cycle figure could not be confirmed in a primary source and was softened to 'months'.
2Challenging
2Mixed findings
Related terms
503B outsourcing facility — An FDA-registered compounding facility that can make larger batches under CGMP standards and FDA inspection — a step above 503A, but still not an FDA-approved manufactured drug.
503A compounding — A section of federal law that lets a licensed pharmacy compound a medication for an individual patient's prescription, outside the FDA approval process.
API (active pharmaceutical ingredient) — The raw drug substance in a medication that produces its effect — for example, semaglutide itself, before it is formulated into a pen or vial.
Certificate of analysis (CoA) — A document reporting the lab test results for a specific batch of a drug ingredient or product, such as identity, purity, and contaminants.
Related guides
"Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you — "Research peptides" are GLP-1 drugs — semaglutide, tirzepatide, retatrutide — sold as powder in vials stamped "research use only, not for human consumption." That label is a legal workaround, not a safety statement. Here's where these products come from, what independent testing actually found inside the vials, why the "research" disclaimer doesn't make them regulated or safe, and the documented harms driving a spike in poison-control calls.
How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board — Our sourcing guides keep ending on the same instruction — verify the pharmacy with your state board, the NABP, or FDA's BeSafeRx — without saying how. This is the step-by-step: the free tools each one offers, what red flags to look for, how to pull a pharmacy's license record, and how to check your own pen's lot number against FDA's counterfeit alerts. About five minutes, start to finish.